Testing a liver scan to detect high pressure in the heart veins
Tests a non-invasive liver stiffness scan in adults with heart failure.
Plain-language title generated from the registry record
Registry title: Evaluation of Liver Stiffness Performance, by FibroScan®, to Detect Elevated Central Venous Pressure (CVP)
Key facts
- Where
- Berlin, GermanySee the site
Where in Germany
- Deutsches Herzzentrum der Charité (DHZC) - Klinik fuer Herz-, Thorax- und GefaesschirurgieBerlin, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Echosens
- Trial code
- NCT07222813
- Record updated
- 23 September 2026
- Original description
This is a pivotal, global, prospective, cross-sectional, multicentric clinical investigation designed to explore a non-invasive, reliable alternative to invasive, catheter-based hemodynamic assessments, which are associated with procedural risks and limited applicability in certain participant populations.Read full original descriptionShow less
Performance of Liver Stiffness Measurement (LSM) by FibroScan® for the Diagnosis of Elevated Central Venous Pressure (CVP)
This is a pivotal, global, prospective, cross-sectional, multicentric clinical investigation designed to explore a non-invasive, reliable alternative to invasive, catheter-based hemodynamic assessments, which are associated with procedural risks and limited applicability in certain participant populations.
Inclusion: Have read, understood, and signed the informed consent form (ICF); Be ≥18 years of age at the time of screening; Have suspected or diagnosed acute or chronic HF and be scheduled to undergo right-sided cardiac catheterization.
Exclusion: Chronic liver disease (self-reported alcohol use >14 drinks/week in females and >21 drinks/week in males), positive hepatitis C virus serology, positive hepatitis B surface antigen, autoimmune hepatitis, hemochromatosis, or cholestatic disease); Heart transplantation; Inability to consent; BMI >40 kg/m2; Fontan-type circulation; Ascites; Pregnancy, breastfeeding, or intent to become pregnant during the study; Intent to donate/bank or retrieve eggs (ova, oocytes) or donate sperm during the study.